News Roche’s Genentech strikes $2.3bn deal for Hanmi obesity drug... Roche’s Genentech has agreed a deal worth up to $2.3 billion to develop and sell Hanmi Pharmaceutical’s experimental obesity drug HM17321.
News Lilly licenses Hanmi GLP-2 drug in $1.26bn deal Eli Lilly's relentless pipeline-building drive has continued with a licensing deal for Hanmi's sonefpeglutide, in phase 2 for short bowel syndrome.
News Lilly axes trial of Hanmi's arthritis drug Lilly may decide to develop drug in other indications
Digital South Korea hopes big data will boost life sciences industry South Korea is to build a comprehensive database of genetic and biometric data from 10 million people, in a bid to boost its pharma and biotech industry.
Views & Analysis Digital Health Round-up – NHS & DeepMind, funding for Apreci... A round-up of this week’s top digital healthcare news. Marco Ricci reports.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.